These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21732248)
21. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814 [TBL] [Abstract][Full Text] [Related]
22. A Comprehensive Structural Overview of p38α Mitogen-Activated Protein Kinase in Complex with ATP-Site and Non-ATP-Site Binders. Astolfi A; Manfroni G; Cecchetti V; Barreca ML ChemMedChem; 2018 Jan; 13(1):7-14. PubMed ID: 29210532 [TBL] [Abstract][Full Text] [Related]
23. Identification of a New Inhibitor That Stabilizes Interleukin-2-Inducible T-Cell Kinase in Its Inactive Conformation. Hantani R; Hanawa S; Oie S; Umetani K; Sato T; Hantani Y SLAS Discov; 2019 Sep; 24(8):854-862. PubMed ID: 31247148 [TBL] [Abstract][Full Text] [Related]
24. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90. Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103 [TBL] [Abstract][Full Text] [Related]
25. A Guide to Run Affinity Screens Using Differential Scanning Fluorimetry and Surface Plasmon Resonance Assays. Bergsdorf C; Wright SK Methods Enzymol; 2018; 610():135-165. PubMed ID: 30390797 [TBL] [Abstract][Full Text] [Related]
26. Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery. Johnson MC; Hu Q; Lingardo L; Ferre RA; Greasley S; Yan J; Kath J; Chen P; Ermolieff J; Alton G J Comput Aided Mol Des; 2011 Jul; 25(7):689-98. PubMed ID: 21779981 [TBL] [Abstract][Full Text] [Related]
27. p38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses. Perry JJ; Harris RM; Moiani D; Olson AJ; Tainer JA J Mol Biol; 2009 Aug; 391(1):1-11. PubMed ID: 19501598 [TBL] [Abstract][Full Text] [Related]
28. Discovery of highly selective inhibitors of p38alpha. Popa-Burke I; Birkos S; Blackwell L; Cheatham L; Clark J; Dickson JK; Galasinski S; Janzen WP; Mendoza J; Miller JL; Mohney RP; Steed PM; Hodge CN Curr Top Med Chem; 2005; 5(10):941-51. PubMed ID: 16178739 [TBL] [Abstract][Full Text] [Related]
29. Fragments: where are we now? Osborne J; Panova S; Rapti M; Urushima T; Jhoti H Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743 [TBL] [Abstract][Full Text] [Related]
30. Screening Ligands by X-ray crystallography. Davies DR Methods Mol Biol; 2014; 1140():315-23. PubMed ID: 24590727 [TBL] [Abstract][Full Text] [Related]
31. Predicting the success of fragment screening by X-ray crystallography. Davies DR; Begley DW; Hartley RC; Staker BL; Stewart LJ Methods Enzymol; 2011; 493():91-114. PubMed ID: 21371588 [TBL] [Abstract][Full Text] [Related]
32. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors. Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283 [TBL] [Abstract][Full Text] [Related]
34. SPR-based fragment screening with neurotensin receptor 1 generates novel small molecule ligands. Huber S; Casagrande F; Hug MN; Wang L; Heine P; Kummer L; Plückthun A; Hennig M PLoS One; 2017; 12(5):e0175842. PubMed ID: 28510609 [TBL] [Abstract][Full Text] [Related]
35. CellFy: A Cell-Based Fragment Screen against C-Type Lectins. Schulze J; Baukmann H; Wawrzinek R; Fuchsberger FF; Specker E; Aretz J; Nazaré M; Rademacher C ACS Chem Biol; 2018 Dec; 13(12):3229-3235. PubMed ID: 30480432 [TBL] [Abstract][Full Text] [Related]
36. Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38alpha MAP kinase. Gill K; Singh AK; Kapoor V; Nigam L; Kumar R; Holla P; Das SN; Yadav S; Subbarao N; Mohanti BK; Dey S Biochim Biophys Acta; 2013 Mar; 1830(3):2763-9. PubMed ID: 23238519 [TBL] [Abstract][Full Text] [Related]
37. Discovering novel P38α inhibitors for the treatment of prostate cancer through virtual screening methods. Li K; Li Z; Tao Y; Wang Q; Lai Y; Wu W; Peng S; Guo Z; Huang H Future Med Chem; 2019 Dec; 11(24):3125-3137. PubMed ID: 31838901 [No Abstract] [Full Text] [Related]
38. The benefits of constructing leads from fragment hits. Foloppe N Future Med Chem; 2011 Jul; 3(9):1111-5. PubMed ID: 21806375 [TBL] [Abstract][Full Text] [Related]
39. Fragment-based drug discovery using a multidomain, parallel MD-MM/PBSA screening protocol. Zhu T; Lee H; Lei H; Jones C; Patel K; Johnson ME; Hevener KE J Chem Inf Model; 2013 Mar; 53(3):560-72. PubMed ID: 23432621 [TBL] [Abstract][Full Text] [Related]
40. Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery. Coutard B; Decroly E; Li C; Sharff A; Lescar J; Bricogne G; Barral K Antiviral Res; 2014 Jun; 106():61-70. PubMed ID: 24704437 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]